Professional Documents
Culture Documents
Medical Progress
H YPERPARATHYROID AND
H YPOPARATHYROID D ISORDERS
STEPHEN J. MARX, M.D.
HE four parathyroid glands, through the secretion of parathyroid hormone, regulate serum
calcium concentrations and bone metabolism.1
In turn, serum calcium concentrations regulate parathyroid hormone secretion; high concentrations inhibit secretion by the parathyroid glands of parathyroid hormone and low concentrations stimulate it.2
Low or falling serum calcium concentrations act within seconds to stimulate parathyroid hormone secretion, initiated by means of a calcium-sensing receptor
on the surface of the parathyroid cells.2 This receptor
is a heptahelical molecule, like the receptors for light,
odorants, catecholamines, and many peptide hormones.3 Parathyroid hormone secretion is 50 percent of the maximal level at a serum ionized calcium
concentration of 4 mg per deciliter (1 mmol per liter); this is considered the calcium set point for parathyroid hormone secretion. A slower regulation of
parathyroid hormone secretion occurs over a period
of hours as a result of cellular changes in parathyroid
hormone messenger RNA (mRNA). Vitamin D and
its metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, acting through vitamin D receptors,
decrease the level of parathyroid hormone mRNA,4
and hypocalcemia increases the level of that mRNA.5,6
The slowest regulation of parathyroid hormone secretion occurs over days or even months and reflects
changes in the growth of the parathyroid glands.
Metabolites of vitamin D directly inhibit the mass of
parathyroid cells7; hypocalcemia stimulates the growth
of parathyroid cells independently of the contrary
action of vitamin D metabolites.8,9 Disruptions in
these processes cause hyperparathyroidism or hypoparathyroidism.
STRUCTURE AND ACTIONS OF
PARATHYROID HORMONE
Parathyroid hormone is stored and secreted mainly as an 84-amino-acid peptide.1 A synthetic aminoterminal fragment, parathyroid hormone (134), is
fully active; modifications at the amino terminal, particularly at the first two residues, can abolish its bioFrom the Metabolic Diseases Branch, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, Md. Address reprint requests to
Dr. Marx at the National Institute of Diabetes and Digestive and Kidney
Diseases, Bldg. 10, Rm. 9C-101, National Institutes of Health, 9000
Rockville Pike, Bethesda, MD 20892-1802, or at StephenM@intra.niddk.
nih.gov.
2000, Massachusetts Medical Society.
Measurements of serum calcium, parathyroid hormone, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D are used regularly in the diagnosis and treatment of hyperparathyroidism and hypoparathyroidism;
only the measurement of serum parathyroid hormone
is covered here. Serum calcium should usually be
measured at the same time as serum parathyroid hormone; since the ionized fraction of serum calcium is
the biologically active form, it is a more useful index
of hyperparathyroidism and hypoparathyroidism than
are other indexes of calcium in serum. It is therefore
the preferred form of serum calcium to measure.
Current assays for serum parathyroid hormone are
two-site assays designed to detect both amino-terminal and carboxy-terminal epitopes of the peptide.14,15
The better assays are those that are well standardized,
do not cross-react with parathyroid hormonerelated peptide, and are sufficiently sensitive that normal
values can be distinguished from subnormal values
(Fig. 2). Parathyroid hormone molecules that are reactive in these two-site immunoassays are considered
intact, but some have no bioactivity.14-17 For example, a loss of only six amino acids to yield parathyroid
hormone (784) eliminates all bioactivity but does
not affect the immunoreactivity measured in most or
all of these assays.10 In fact, about half of the parathyroid hormone detected with these assays in the
serum of patients with chronic renal disease is biologically inactive.16,17
Measurements of parathyroid hormone can help
characterize parathyroid tumors. Parathyroid hormone
can be measured in fluid obtained from a lesion by
fine-needle aspiration (usually guided ultrasonographically) or in serum from the veins of the neck and
mediastinum, catheterized selectively.18 Serum test results that can be obtained in 10 to 15 minutes allow
physicians to assess the completeness of the removal
Vo l u m e 3 4 3
Nu m b e r 2 5
1863
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
Extracellular ionized 6
calcium
Renal6
tubule
Calcium-6
sensing6
receptor
Ca2+
PTH6
receptor
Parathyroid cell
Ca2+
Bone
PTH
Calcium-6
sensing6
receptor
1,25(OH)2D
Endocrine6
mechanism6
6
Ca2+
PTHrP
Duodenal6
lumen
Blood and other6
extracellular fluid
PTHrP
Autocrineparacrine6
mechanism
PTH receptor
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
10,000
1,000
Uremic6
hyperpara-6
thyroidism
Primary6
hyperparathyroidism
100
Normal
10
Tumor6
hypercalcemia
Primary6
hyperpara-6
thyroidism
Lower limit6
of detection
6
10
11
12
13
14
15
Solitary parathyroid adenomas account for 85 percent of cases of primary hyperparathyroidism; hyperfunction in multiple parathyroid glands (a broad catVo l u m e 3 4 3
Nu m b e r 2 5
1865
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
Secretory6
granule
Menin
JunD
PTH
CDK 4 or 6
p53
E2F
Cytoplasm
DNA
Cyclin3
D1
pRb
RET
Nucleus
G?
SHC
RRL
Calcium-sensing6
receptor
Ca2+
RR-GPI
Plasma membrane
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
Among the minority of patients with primary hyperparathyroidism caused by hyperfunction of multiple parathyroid glands, the disorder is inherited in
about 20 percent. Any of these hereditary syndromes,
such as multiple endocrine neoplasia type 1, may
present as isolated hyperparathyroidism in some families.38,47,48 Each syndrome raises special issues for diagnosis and management (Table 1).
Multiple Endocrine Neoplasia Type 1
TABLE 1. CATEGORIES
OF
by an inactivating germ-line mutation of a tumorsuppressor gene (the MEN1 gene) that is inherited
as an autosomal dominant trait. Acquired or somatic
mutation of the second MEN1 copy can give a cell
the growth advantage to become a tumor.
Familial Hypocalciuric Hypercalcemia
PRIMARY HYPERPARATHYROIDISM.*
MULTIPLE ENDOCRINE
NEOPLASIA TYPE 1
FAMILIAL HYPOCALCIURIC
HYPERCALCEMIA
CHARACTERISTIC
SPORADIC ADENOMA
Inheritance
Age at onset of
hypercalcemia
Urinary calcium excretion
Serum parathyroid hormone
concentration
Parathyroid glands
No. abnormal
Enlargement
Clonality
Effectiveness of
parathyroidectomy
Pathophysiology
Not inherited
55 yr
Autosomal dominant
25 yr
Autosomal dominant
Birth
Autosomal recessive
Birth
Normal to high
High
Normal to high
High
Low to normal
Normal
Low to normal
Very high
One
20 times normal size
Monoclonal or oligoclonal
95% cured
Multiple
5 times normal size
Monoclonal or oligoclonal
90% cured, but many recur
Multiple
Minimally enlarged
Polyclonal
Surgery not indicated
Sequential inactivation of both Monoallelic inherited inacticopies (first copy by inheritvation of the calcium-sensance) of the MEN1 gene
ing receptor gene decreases
leads to the growth of one or
the sensing of serum calcimore neoplastic clones in parum by parathyroid cells and
athyroid glands
by renal tubules
Multiple
Very enlarged
Polyclonal
Total parathyroidectomy
required
Biallelic inactivation of the
calcium-sensing receptor
gene impairs calcium
sensing in parathyroid
cells more than does
monoallelic inactivation
*All entries are typical for that disorder. Ranges are broad, with overlap (not shown) among categories.
Vo l u m e 3 4 3
Nu m b e r 2 5
1867
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
Multiple endocrine neoplasia type 2a is characterized primarily by medullary thyroid carcinoma and
pheochromocytoma.27 Primary hyperparathyroidism
can occur by the age of 70 in up to 70 percent of
patients and is usually mild.51 Multiple endocrine neoplasia type 2a is caused by an activating mutation of
the RET proto-oncogene and is inherited as an autosomal dominant trait.27
HyperparathyroidismJaw Tumor Syndrome
1868
In most patients, primary hyperparathyroidism progresses slowly, if at all. Among asymptomatic patients,
only about 25 percent have progressive disease, which
is usually manifested as a decrease in bone mass during a 10-year period of follow-up.55 Thus, there has
been some controversy regarding the indications for
surgery, the only effective treatment. A consensus conference of the National Institutes of Health concluded in 1990 that surgery was not routinely needed in
asymptomatic patients 50 years old or older who
had a serum calcium concentration 1.0 to 1.6 mg per
deciliter (0.25 to 0.40 mmol per liter) above the upper limit of normal, a level of urinary calcium excretion of less than 400 mg (100 mmol) per day, a creatinine clearance of at least 70 percent of normal, or
a z score higher than 2 for bone mass.67 These are
still reasonable guidelines, but surgery may be recommended for many of these patients because of the
evidence that it ameliorates neurobehavioral symp-
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
Parotid
Submandibular
Thyroid
Mediastinal6
parathyroid
Heart
Figure 4. Anterior Planar Image of the Neck and Chest of a Patient with Primary Hyperparathyroidism Obtained with Technetium-99m Sestamibi, Showing a Parathyroid Adenoma in the
Mediastinum.
The patient had undergone an unsuccessful parathyroid exploration. The image shown was obtained two hours after the administration of 20 mCi of the radionuclide. The lobes of the thyroid and the salivary glands are clearly visible. (Image courtesy
of Dr. Clara Chen.)
HYPERCALCEMIA MEDIATED BY
PARATHYROID HORMONERELATED
PEPTIDE
Hypercalcemia is sometimes caused by serum factors, which may be released by nonparathyroid tumors, whether or not there are skeletal metastases.
Most of these tumors are malignant and secrete parathyroid hormonerelated peptide.13 In contrast, hypersecretion of parathyroid hormone by a nonparathyroid tumor is extremely rare.
UREMIC HYPERPARATHYROIDISM
Secondary and Tertiary Hyperparathyroidism
Hypocalcemia from any cause stimulates parathyroid hormone secretion, and chronic hypocalcemia
also stimulates the growth of the parathyroid glands.
This secondary hyperparathyroidism usually resolves
with the treatment of the underlying cause of hypocalcemia. However, in patients with chronic renal failure, secondary hyperparathyroidism often lasts longer
and is more severe than in patients with other hypocalcemic disorders, such as a deficiency or malabsorption of vitamin D.80 Eventually, either before or, more
often, after renal transplantation, secondary hyperparathyroidism can develop into a disorder of oversecretion of parathyroid hormone with hypercalcemia (tertiary hyperparathyroidism).
The Parathyroid Gland in Uremia
Nu m b e r 2 5
1869
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
TABLE 2. TREATMENTS
PROCESS AFFECTED
BY
FOR
HYPERPARATHYROIDISM
HYPOPARATHYROIDISM.
TREATMENTS FOR
HYPERPARATHYROIDISM
TREATMENT
AND
Parathyroidectomy
Calcium-sensingreceptor agonist*
Blocker of type 1 receptor*
Bisphosphonates
Estrogen
Blocker of vitamin D receptor*
Forced natriuresis
Dialysis
TREATMENTS FOR
HYPOPARATHYROIDISM
Parathyroid autograft
Parathyroid hormone (134)*
Vitamin D analogue
Calcium salts
Thiazide
Intravenous calcium
ease among patients with uremia is similar to the frequency of adynamic bone diseases.86,87
Uremic hyperparathyroid bone disease is best treated by raising serum calcium concentrations and thereby decreasing parathyroid hormone secretion. The
cause of adynamic bone disease is not known, and
there is no specific treatment.88,89
Treatment of Hyperparathyroidism in Patients
with Chronic Renal Diseases
In patients with chronic renal failure, secondary hyperparathyroidism is caused by hypocalcemia, which,
in turn, is caused by hyperphosphatemia and decreased
renal production of 1,25-dihydroxyvitamin D. Treatment is based on raising serum calcium concentrations by the oral administration of calcium salts; these
salts also ameliorate hyperphosphatemia by chelating
phosphate in the intestines. Additional measures for
treating hypocalcemia include raising the calcium
concentration in the dialysis fluid and administering
some form of vitamin D. When treatment is initiated
early, severe secondary hyperparathyroidism can be
prevented or at least delayed. There is some controversy regarding the most appropriate dosage, type, and
route of administration of vitamin D or vitamin D
analogue90,91 and the most appropriate phosphate
binder for these patients.92 1,25-Dihydroxyvitamin D3
(calcitriol) has sometimes been given intravenously
in pulsed doses in the hope of inhibiting parathyroid
hormone secretion without raising serum calcium concentrations,90,91 but calcitriol given orally has similar
effects.93
Severe secondary hyperparathyroidism is an important indication for parathyroidectomy in patients
with chronic renal disease who cannot be treated adequately with the measures described above.94 Parathyroidectomy is also appropriate for some patients
with tertiary hyperparathyroidism.
After renal transplantation, secondary hyperpara-
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
Injury to or removal of the parathyroid glands during neck surgery is the most common cause of acute
or chronic hypoparathyroidism.
Developmental Defects in the Parathyroid Glands
Agenesis of the parathyroid glands occurs in infants with the DiGeorge syndrome (and the closely
related velocardiofacial syndrome). The manifestations
of these syndromes include incomplete development
in the branchial arches, resulting in varying degrees
of parathyroid and thymic hypoplasia, conotruncal
cardiac defects, facial malformations, and learning disability. Both syndromes are associated with rearrangements and microdeletions affecting an unknown gene
or genes on the short arm of chromosome 22.97 Any
resultant defect should be treated, depending on its
severity.98 Isolated agenesis of the parathyroid glands
in one family has been attributed to a recessive deletion in the gene on chromosome 6 that normally
encodes a transcription factor.99
Autoimmune Hypoparathyroidism
diasisectodermal dystrophy syndrome.100 The hypoparathyroidism, like other manifestations of the syndrome, occurs during childhood; for this reason and
because of such associated abnormalities as hypoadrenalism and intestinal malabsorption, the hypoparathyroidism may be difficult to treat. The syndrome is inherited as an autosomal recessive trait and is caused by
mutations in an autoimmune regulator gene (AIRE)
with a known sequence but an unknown function.101
Defects in the Parathyroid Hormone Molecule
Hypocalcemia and hypercalciuria are the chief features of autosomal dominant hypercalciuric hypocalcemia, which is caused by activating mutations of the
parathyroid and renal calcium-sensing receptor. These
mutations cause excessive calcium-induced inhibition
of parathyroid hormone secretion. The hypocalcemia
is usually mild and asymptomatic. When it is mild,
it should be treated cautiously, if at all, because raising serum calcium concentrations further increases
urinary calcium excretion and may cause nephrocalcinosis.41,103
TREATMENT OF HYPOPARATHYROIDISM
Calcium and Vitamin D Analogues
Nu m b e r 2 5
1871
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
Pseudo-pseudohypoparathyroidism occurs in families with pseudohypoparathyroidism type 1a. It consists of a combination of inactivating mutations of
GNAS1 and Albrights osteodystrophy without the
resistance to multiple hormones that characterizes
pseudohypoparathyroidism. The hormone resistance
is suppressed when the mutated GNAS1 gene is inherited from the father (i.e., paternal imprinting, or
suppression, of the mutant copy occurs in selected
tissues).107,108
Pseudohypoparathyroidism Type 1b
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
Vo l u m e 3 4 3
Nu m b e r 2 5
1873
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne
1874
De c e m b e r 2 1 , 2 0 0 0
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
MEDICAL PROGRESS
pocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996;335:1115-22.
104. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid
hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6.
105. Schipani E, Langman CB, Parfitt AM, et al. Constitutively activated
receptors for parathyroid hormone and parathyroid hormonerelated peptide in Jansens metaphyseal chondrodysplasia. N Engl J Med 1996;335:
708-14.
106. Zhang P, Jobert AS, Couvineau A, Silve C. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related
Vo l u m e 3 4 3
Nu m b e r 2 5
1875
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
CORRECTION
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.
CORRECTION
Downloaded from www.nejm.org on June 28, 2010 . Copyright 2000 Massachusetts Medical Society. All rights reserved.